01
What we do
We are a biopharmaceutical research and development company founded to accelerate the commercialization of novel bacteriophage-based products for the treatment of bacterial infectious diseases, including both antibiotic-sensitive and antibiotic-resistant infections.
Products in development target bacterial pathogens that cause resistant infections in significant human populations.
In addition to sensitive and resistant forms of Staphylococcus aureus (MSSA & MRSA), we analyze and differentiate patients’ anti-staphylococcal bacteriophages against other Staphylococcus spp.—an emerging group of invasive, opportunistic pathogens affecting the immune system—using our advanced diagnostic methods.
02
Our Approach
We have brought together leading and renowned scientists to work with us on a solution for methicillin-resistant Staphylococcus aureus (MRSA), giving many people a renewed chance for recovery.
03
Our Mission
Our company was founded to develop bacteriophage-based antimicrobial products for the treatment of respiratory and systemic infections caused by Staphylococcus aureus (S. aureus) and other Staphylococcus species. Antibiotic resistance is rising to dangerously high levels, which is why we must rethink existing standards and develop new solutions.
About Our Company
For years, we have been researching the treatment of complex multidrug-resistant Staphylococcus aureus (MRSA) infections and have successfully developed suitable therapies to treat these resistant infections.
Building on our research results and developments, Phage Therapeutics will bring bacteriophage-based medicines to market, developed by a global team of highly experienced researchers and managers in Switzerland and Germany—two of the most innovative countries in the pharmaceutical industry.
Antibiotic resistance is rising to dangerously high levels
The WHO states: “Without urgent action, we are heading toward a post-antibiotic era in which common infections and minor injuries could once again be fatal.”
We have been facing a global antibiotic crisis for years. Antibiotic resistance data for 2019 indicates approximately more than 5.0 million deaths caused by resistant pathogens, with numbers rising rapidly each year. Source: ZEIT ONLINE, January 20, 2022.
For comparison: In 2020, an estimated 680,000 people died from HIV/AIDS and 627,000 from malaria.
46,2
Millions of antibiotics are prescribed unnecessarily every year.
65%
of antibiotics are prescribed unnecessarily every year.
1939
The first antibiotic was introduced
Behind Phage Therapeutics
Established and renowned scientists have come together to find a solution to this crisis.
We have assembled a global team to help avert the impending antibiotic crisis.
Mr. Balz holds an MBA and has many years of experience in the pharmaceutical industry as a certified clinical consultant and as a director of a globally operating pharmaceutical company.
Hans Balz
Chief Executive Officer
